Peter MacCallum Cancer Centre, Affymetrix collaborate
Five-year collaboration to analyze genomic information across large patient samples.
| 1 min read
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
Here are some related topics that may interest you:
SANTA CLARA, Calif.—Affymetrix Inc. announced that it entered into a five-year collaboration with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia, to analyze genomic information across large patient samples. Under terms of the agreement, Peter Mac researchers will use Affymetrix GeneChip microarray technology for translational research projects, beginning with studies on ovarian cancer and carcinoma of unknown primaries.
Peter Mac researchers will use Affymetrix GeneChip technology to perform large-scale clinical studies. The Affymetrix technology will enable them to more rapidly discover RNA and DNA patterns that can better classify, manage and treat complex diseases.
"We are excited about the opportunities created by the Translational Medicine Program, particularly the chance to apply new technologies to help us answer important clinical questions," says Dr. David Bowtell, director of research at the Peter MacCallum Cancer Centre. "We are keen to help our collaborators across Australia gain access to Affymetrix technology, as we continue to develop as a major center for cancer genomics and genetics. We also see the program providing opportunities to interact with other centers worldwide that are involved in translational research."
Affymetrix collaborates with academic institutions, advocacy groups and the pharmaceutical and diagnostics community through its Translational Medicine Program to develop molecular signatures for improving patient care. Affymetrix GeneChip microarray technology helps researchers to diagnose and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
The Translational Medicine Program complements the Powered by Affymetrix program, which enables companies to license GeneChip technology to create innovative, custom-designed microarray products based on signatures such as those of its translational medicine partners. This technology is already being used in many applications, including diagnostics, forensics, and animal, industrial and food testing.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
